Looking into the crystal ball: predicting the aggregation propensity of antibodies

Fully automated analysis of antibody formulations using chemical and thermal denaturation

One of the most important parameters in the development of therapeutic biologics is their long-term stability. Despite appearing stable in various formulations once purified, many antibodies display very slow aggregation kinetics over time. Thus far, this gradual aggregation could only be evaluated by monitoring monomer and aggregate content over months, or even years. Predictive methods for monitoring aggregation would address this urgent technology gap and help speed up the development timeline of biologics.